J. Safra Sarasin Holding AG Acquires New Shares in Edwards Lifesciences Corporation $EW

J. Safra Sarasin Holding AG bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,558 shares of the medical research company’s stock, valued at approximately $1,054,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $28,000. True Wealth Design LLC raised its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the period. NewSquare Capital LLC lifted its position in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. Rakuten Securities Inc. lifted its position in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new position in Edwards Lifesciences during the third quarter worth about $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. National Bankshares set a $92.00 target price on Edwards Lifesciences in a research report on Friday, October 31st. Truist Financial set a $92.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, December 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $98.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Tuesday, January 20th. Finally, Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $96.82.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president directly owned 31,870 shares in the company, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 57,824 shares of company stock valued at $4,863,323 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Down 2.1%

Edwards Lifesciences stock opened at $81.86 on Thursday. The firm has a market capitalization of $47.50 billion, a P/E ratio of 35.28, a P/E/G ratio of 3.22 and a beta of 0.95. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The stock’s fifty day simple moving average is $84.89 and its 200-day simple moving average is $80.94.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.